Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

Clover Bio’s SCB-1019 Vaccine Candidate Shows Promising Results in Phase I Trial

Fineline Cube Apr 9, 2024

Clover Biopharmaceuticals (HKG: 2197), a leading biotechnology company based in China, has announced robust preliminary...

Company Drug

Bristol Myers Squibb Reports Positive Long-Term Data for KarXT in Schizophrenia Trial

Fineline Cube Apr 9, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced preliminary long-term data from a...

Company Drug

Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202

Fineline Cube Apr 9, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from...

Company Deals Drug Medical Device

Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab

Fineline Cube Apr 9, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent...

Company Drug

CStone Pharmaceuticals Submits New Drug Application for Gavreto in China, Eyes Local Manufacturing

Fineline Cube Apr 9, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has submitted a market...

Company Deals

Medicxi-Led Investment Boosts D3 Bio’s Development of Best- in-Class Oncology Therapies

Fineline Cube Apr 9, 2024

UK life sciences investment firm Medicxi has taken the lead in a $62 million Series...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA

Fineline Cube Apr 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...

Company Drug

Abbisko Therapeutics Achieves Milestone in Global Phase III Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor

Fineline Cube Apr 9, 2024

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the completion of subject...

Company Drug

Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101

Fineline Cube Apr 9, 2024

Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...

Company Medical Device

Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China

Fineline Cube Apr 8, 2024

Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the...

Company Deals

Merck Collaborates with Caris Life Sciences to Develop First-in-Class Antibody-Drug Conjugates

Fineline Cube Apr 8, 2024

German pharmaceutical giant Merck (ETR: MRK) has entered into a strategic collaboration with Caris Life...

Company Deals

Johnson & Johnson Acquires Shockwave Medical in a Landmark Deal to Expand Cardiovascular Portfolio

Fineline Cube Apr 8, 2024

Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has announced the acquisition of Shockwave Medical...

Policy / Regulatory

China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus

Fineline Cube Apr 8, 2024

The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...

Company Drug

AstraZeneca’s Imfinzi Achieves Positive Results in Late-Stage Trial for Small Cell Lung Cancer

Fineline Cube Apr 8, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that a late-stage trial for its...

Company Drug

Novartis’s Leqvio Showcases Real-World Efficacy in Managing Cholesterol in ASCVD Patients

Fineline Cube Apr 8, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small...

Policy / Regulatory R&D

Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development

Fineline Cube Apr 8, 2024

The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...

Policy / Regulatory

Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth

Fineline Cube Apr 8, 2024

In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Secures FDA Approval for HER2-Positive Solid Tumors

Fineline Cube Apr 8, 2024

Partners AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have been granted an additional...

Company Drug

Bristol Myers Squibb’s Abecma Receives FDA Approval for Wider Use in Multiple Myeloma Treatment

Fineline Cube Apr 8, 2024

The US Food and Drug Administration (FDA) has granted an indication extension for Bristol Myers...

Company

Sanofi Announces Sweeping Restructuring and Layoffs in Pipeline Reprioritization Effort

Fineline Cube Apr 8, 2024

Paris-based pharmaceutical giant Sanofi (NASDAQ: SNY) is embarking on a comprehensive “full pipeline reprioritization” that...

Posts pagination

1 … 416 417 418 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.